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Abstract
 
TWEAK, a new member of the tumor necrosis factor (TNF) family, induces cell death in some
tumor cell lines, but its physiological functions are largely unknown. In this study, we investi-
gated the expression and function of TWEAK in human peripheral blood mononuclear cells
(PBMCs) by using newly generated anti–human TWEAK mAbs. Although freshly isolated
PBMCs expressed no detectable level of TWEAK on their surfaces, a remarkable TWEAK ex-
pression was rapidly observed on monocytes upon stimulation with interferon (IFN)-
 
g
 
 but not
with IFN-
 
a
 
 or lipopolysaccharide. Cytotoxic activity of IFN-
 
g
 
–stimulated monocytes against
human squamous carcinoma cell line HSC3 was inhibited partially by anti-TWEAK mAb
alone and almost completely by combination with anti-TRAIL (TNF-related apoptosis-induc-
ing ligand) mAb. These results revealed a novel pathway of monocyte cytotoxicity against tu-
mor cells that is mediated by TWEAK and potentiated by IFN-
 
g
 
.
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Introduction
 
Some members of the TNF family, such as TNF-
 
a
 
, Fas
ligand (FasL), and TNF-related apoptosis-inducing ligand
(TRAIL) induce apoptotic cell death in a variety of tumor
cells and nontransformed cells (1–3). These molecules have
been characterized as playing critical roles in regulating im-
mune responses and in the pathogenesis of various diseases
(1–3). TWEAK is a recently identified member of the TNF
family that exhibited cytotoxic activity against some tumor
cell lines in vitro (4–6). It has also been reported that
TWEAK activated nuclear factor (NF)-
 
k
 
B in some tumor
cells (4) and induced proliferation of endothelial cells and
angiogenesis (7). TWEAK mRNA has been found in vari-
ous tissues and cell lines (4). However, its expression at the
protein level and physiological roles remain largely un-
known. It has been reported that TWEAK bound to DR3/
TRAMP/LARD/APO-3/WSL1 (5), which is a member
of the TNFR family containing cytoplasmic death domain
(DD) homologous to that in TNFR-I, Fas, TRAIL-R1,
and TRAIL-R2 (8). Like TNFR-I, DR3 could induce
both apoptosis and NF-
 
k
 
B activation by recruiting TNFR-
I–associated DD protein (TRADD), TNFR-associated fac-
tor (TRAF) 2, Fas-associated DD protein (FADD), and
caspase-8 (8). However, some conflicting results have been
reported as to the TWEAK–DR3 interaction. For exam-
ple, a study by Chicheportiche et al. (4) failed to demon-
strate the binding of TWEAK to DR3. In addition, it has
been reported that TWEAK induced apoptosis in KYM-1
cells lacking DR3 mRNA expression (6). These reports
suggest the existence of unidentified TWEAK receptor dis-
tinct from DR3.
It is well known that monocytes play important roles in
innate immunity and inflammatory responses via produc-
tion of various cytokines and chemical mediators. In addi-
tion, previous studies indicated that monocytes kill some
tumor cells directly and that IFNs are an effective inducer
of monocyte cytotoxicity (9, 10). TNF-
 
a
 
 and nitric oxide
(NO) have been considered to be the major mediators for
IFN-stimulated monocyte cytotoxicity (9, 11). However,
there are conflicting data as to the involvement of TNF-
 
a
 
and NO, especially in the human system. For example, it
has been reported that both IFN-
 
a
 
 and IFN-
 
g
 
 failed to in-
duce NO release and TNF-
 
a
 
 production by human mono-
cytes (12, 13). Recently, Griffith et al. (13) have shown a
critical contribution of TRAIL to the IFN-
 
a
 
– or IFN-
 
g
 
–
activated monocyte cytotoxicity against TRAIL-sensitive
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tumor cells. In that study, they demonstrated that similar
levels of TRAIL expression could be induced on mono-
cytes upon stimulation with IFN-
 
a
 
 or IFN-
 
g
 
. However, in
general, IFN-
 
g
 
 is a much more potent inducer of mono-
cyte cytotoxicity than IFN-
 
a
 
 (10). This suggests a possible
existence of additional death-inducing molecule(s) on
monocytes that can be specifically inducible upon IFN-
 
g
 
stimulation.
In this study, by using newly generated neutralizing
mAbs against human (h)TWEAK, we examined the ex-
pression and function of TWEAK in human PBMCs.
TWEAK was not found on freshly isolated PBMCs but
was preferentially inducible on monocytes upon IFN-
 
g
 
stimulation. We demonstrated that TWEAK is at least
partly responsible for the IFN-
 
g
 
–stimulated monocyte cy-
totoxicity against TWEAK-sensitive tumor cells. These re-
sults suggested possible roles for TWEAK in antitumor
activity and inflammatory responses mediated by IFN-
 
g
 
–
stimulated monocytes.
 
Materials and Methods
 
Cells.
 
Mouse B lymphoma 2PK-3, T lymphoma L5178Y,
myeloma P3U1 (P3X63Ag8U.1), and human colon adenocarci-
noma HT-29 were obtained from American Type Culture Col-
lection and cultured in RPMI 1640 containing 10% FCS, 100
 
m
 
g/ml streptomycin and penicillin, and 2 mM glutamine (culture
medium). Human oral squamous cell carcinoma HSC3 and gas-
tric adenocarcinoma KATO-III were obtained from Japan Can-
cer Research Bank and maintained in the culture medium. 2PK-
3–derived transfectants, including hTWEAK/2PK-3, hTRAIL/
2PK-3 (14), and hFasL/2PK-3 (15), were also maintained in the
culture medium.
 
Reagents.
 
Human IFN-
 
g
 
, GM-CSF, TNF-
 
a
 
, IL-4, IL-15,
and anti–TNF-
 
a
 
 mAb (mAb1) were purchased from PharMin-
gen. Human IL-12 was purchased from R & D Systems. Human
IL-2, IFN-
 
a
 
, and IL-18 were provided by Shionogi, Toray, and
Drs. H. Tsutsui, H. Okamura, and K. Nakanishi (Hyogo College
of Medicine, Nishinomiya, Japan), respectively. PHA and LPS
were purchased from Wako Pure Chemical, Ltd. Anti-CD3 mAb
was purified from the supernatant of the hybridoma (OKT-3)
purchased from American Type Culture Collection. A neutraliz-
ing anti–human TRAIL mAb (RIK-2, mouse IgG1/
 
k
 
) was pre-
pared as described previously (14). Control mouse IgG3 mAb
(J606) and mouse IgM mAb (C48-6) were purchased from
PharMingen.
 
Construction and Preparation of Soluble CD8–TWEAK Fusion
Protein.
 
hTWEAK cDNA was prepared by reverse transcription
PCR amplification of total RNA from human PBMCs with an
oligonucleotide primer corresponding to the first six codons as
the 5
 
9
 
 primer and that corresponding to the last six codons as the
3
 
9
 
 primer, according to the published sequence (4). The PCR
product of 750 bp was subcloned into pCR3.1 TA cloning vec-
tor (Invitrogen), and the nucleotide sequence was confirmed us-
ing an automated sequencer (Applied Biosystems) and a fluores-
ceinated dye terminator cycle sequencing method. The cDNA
encoding extracellular region of hTWEAK (amino acids 93–249)
was amplified by PCR from the pCR3.1 plasmid carrying
hTWEAK cDNA using AGAAGTGCACCTAAAGGC as the 5
 
9
 
primer and GAGAAGGTCCAAGTGACT as the 3
 
9
 
 primer.
EcoRV and NotI sites were introduced into the 5
 
9
 
 and 3
 
9
 
 prim-
 
ers, respectively. After EcoRV and NotI digestion, the PCR
product of 470 bp was subcloned into HindIII- and NotI-
digested pBluescript II SK (
 
1
 
), together with the 700-bp Hind-
III–EcoRV fragment encoding the extracellular region of human
CD8
 
a
 
, which was derived from pGEM3 carrying human CD8
 
a
 
cDNA (16) (provided by H. Nakauchi, Tsukuba University,
Tsukuba, Japan). This results in in-frame fusion of the human
CD8
 
a
 
 extracellular region to TWEAK (CD8–TWEAK). After
confirmation of nucleotide sequence, the 1.2-kb XhoI–NotI
fragment containing the fusion construct was transferred into
XhoI–NotI sites of pMKITNeo (provided by Dr. K. Maruyama,
Tokyo Medical and Dental University, Tokyo, Japan). COS7
cells were transfected with CD8–TWEAK/pMKITNeo by the
standard DEAE dextran method. After 72-h culture, the superna-
tant was collected, and the concentration of CD8–TWEAK solu-
ble fusion protein was evaluated by sandwich ELISA using two
anti-CD8
 
a
 
 mAbs (RPA-T8 and biotinylated OKT8) as described
previously (16). Affinity-purified CD8–FasL (16) was used as
standard.
 
Preparation of hTWEAK Transfectants.
 
hTWEAK/pCR3.1
vector was transfected into 2PK-3 cells (350 V, 800 
 
m
 
F) with a
Gene Pulser (Bio-Rad Laboratories). After selection with 1 mg/
ml G418 and cloning by limiting dilution, a stable transfectant,
designated as hTWEAK/2PK-3, was selected by cytotoxic assay
as described below. In a similar way, L5178Y cells stably express-
ing hTWEAK (hTWEAK/L5178Y) were prepared.
 
Generation of Anti-hTWEAK mAbs.
 
6-wk-old female BALB/c
mice (Clear Japan) were immunized by intraperitoneal injection
of hTWEAK/2PK-3 (10
 
7
 
 cells) four times at 10-d intervals. 3 d
after the final immunization, the splenocytes were fused with
P3U1 mouse myeloma cells as described previously (14). After
HAT selection, the mAbs that inhibited cytotoxic activity of
CD8–TWEAK against HSC3 cells were screened. Two mAbs
(CARL-1 and CARL-2) were identified by their inhibitory ef-
fects and cloned by limiting dilution. CARL-1 (mouse IgG3/
 
k
 
)
and CARL-2 (mouse IgM/
 
k
 
) were purified from culture super-
natants with a protein G column (Amersham Pharmacia Biotech)
and a protein L column (CLONTECH Laboratories, Inc.), re-
spectively.
 
51
 
Cr-Release Assay.
 
51
 
Cr-labeled target cells (10
 
4
 
) and effector
cells were mixed in U-bottomed wells of a 96-well microtiter
plate at the indicated E/T ratios. After 8 or 18 h of incubation,
cell-free supernatants were collected, and radioactivity was mea-
sured in a gamma counter. The percentage of specific 
 
51
 
Cr release
was calculated as described before (14). RIK-2, CARL-1, and/or
anti–TNF-
 
a
 
 mAbs were added to a final concentration of 10 
 
m
 
g/
ml at the start of cytotoxic assay.
 
Cell Viability Assay.
 
Tumor cells (5 
 
3
 
 10
 
3
 
)
 
 
 
were cultured
with or without the indicated doses of CD8–TWEAK and/or
IFN-
 
g
 
 (20 ng/ml) for 36 h in flat-bottomed wells of a 96-well
microtiter plate. The cell viability was then determined by WST
assay using a Cell Counting kit (Wako Pure Chemical, Ltd.) ac-
cording to the manufacturer’s instructions.
 
Flow Cytometric Analysis.
 
2PK-3 and hTWEAK/2PK-3 cells
(10
 
6
 
 cells) were incubated with 0.5 
 
m
 
g of biotinylated mAb for
1 h at 4
 
8
 
C, followed by PE-labeled avidin (PharMingen). After
washing with PBS, the cells were analyzed on a FACSCalibur™
(Becton Dickinson), and the data were processed by using the
CELLQuest™ program (Becton Dickinson). In some experi-
ments, PBMCs or purified monocytes were stained with 0.5 
 
m
 
g
of biotinylated mAbs, followed by PE-labeled avidin and Cy-
Chrome–labeled anti-CD3 mAb, FITC-labeled anti-CD19, anti-
CD56, or anti-CD14 mAb (PharMingen). 
1375
 
Nakayama et al. Brief Definitive Report
 
Cell Preparation and Activation.
 
PBMCs were prepared from
healthy volunteers by Ficoll-Hypaque (Sigma-Aldrich) centrifu-
gation. PBMCs (10
 
6
 
 cells/ml) were cultured at 37
 
8
 
C for 24 or 48 h
on 24-well plates precoated with anti-CD3 mAb (10 
 
m
 
g/ml) or
in the presence of PHA (20 
 
m
 
g/ml), IFN-
 
a
 
 (200 U/ml), IFN-
 
g
 
(100 ng/ml), IL-2 (500 U/ml), IL-4 (50 ng/ml), IL-10 (50 ng/
ml), IL-12 (20 ng/ml), IL-15 (150 ng/ml), or IL-18 (500 ng/ml).
For preparation of monocytes, PBMCs were cultured on tissue
culture dishes precoated with FCS for 1 h at 37
 
8
 
C. After removal
of nonadherent cells, adherent cells were detached by suspending
in ice-cold PBS containing 0.5% EDTA and then resuspended in
the culture medium. Monocytes were further purified using a
monocyte negative isolation kit (Dynal) according to the manu-
facturer’s instructions. Purity of monocytes used was 
 
.
 
93%
CD14
 
1
 
 
 
as
 
 
 
estimated by flow cytometry.
 
Results
 
Characterization of Recombinant Soluble hTWEAK and
hTWEAK Transfectants.
 
To characterize the functional
properties of hTWEAK, we generated a soluble CD8–
TWEAK fusion protein and stable cDNA transfectants ex-
pressing full-length hTWEAK. First, we constructed a
CD8–TWEAK fusion protein composed of the extracellu-
lar domain of hTWEAK (amino acids 93–249) and human
CD8
 
a
 
, as we previously generated a functional soluble
form of FasL (16). We examined the cytotoxic activity of
 
CD8–TWEAK against some tumor cell lines in the pres-
ence or absence of IFN-
 
g
 
. As previously reported by others
(4), colon adenocarcinoma HT-29 cells were highly sensi-
tive to TWEAK-induced cell death only in the presence of
IFN-
 
g
 
 (Fig. 1 A). Gastric adenocarcinoma KATO-III cells
were also weakly sensitive to TWEAK only in the presence
of IFN-
 
g
 
. In contrast, oral squamous carcinoma HSC3 cells
were highly sensitive to TWEAK even in the absence of
IFN-
 
g
 
 (Fig. 1 A).
We next generated stable transfectants expressing full-
length TWEAK cDNA. Mouse B lymphoma 2PK-3
cells, which were totally resistant to CD8–TWEAK-
induced cytotoxicity (data not shown), were transfected
with hTWEAK/pCR3.1 by electroporation to make
hTWEAK/2PK-3 cells. To verify the expression of
TWEAK in hTWEAK/2PK-3 cells, we tested the cyto-
toxic activity of the transfectant against HSC3 target cells in
8- or 18-h 
 
51
 
Cr-release assay, along with the parental
2PK-3 cells, human FasL transfectant (hFasL/2PK-3), and
hTRAIL transfectant (hTRAIL/2PK-3). As represented in
Fig. 1 B, all of these transfectants lysed HSC3 target cells
significantly, whereas no cytotoxicity was observed with
the parental 2PK-3 cells. In contrast to a rapid time course
of FasL-induced cytotoxicity, which reached a peak at 8 h,
a more prolonged period of 18 h was required to substan-
tially detect TWEAK- or TRAIL-induced cytotoxicity.
Figure 1. Cytotoxic activity of TWEAK against tumor cell lines. (A) Cytotoxic activity of CD8–TWEAK. Target tumor cells (5 3 103) were cultured
with the indicated concentrations of CD8–TWEAK in the presence (d) or absence (s) of IFN-g (20 ng/ml). After 36-h culture, viability was estimated by
the WST assay. Data represent mean 6 SD of triplicate samples. Similar results were obtained in three independent experiments. (B) Cytotoxic activity of
hTWEAK, hTRAIL, and hFasL transfectants against HSC3 cells. Cytotoxic activity of the indicated transfectants was tested against HSC3 cells in 8- (white
bars) or 18-h (gray bars) 51Cr-release assay at an E/T ratio of 10. Data represent mean 6 SD of triplicate samples. Similar results were obtained in three in-
dependent experiments. (C) Cytotoxic activity of hTWEAK or hTRAIL transfectants against KATO-III and HSC3 cells. Cytotoxic activity of hTWEAK/
2PK-3 (d), hTRAIL/2PK-3 (s), or 2PK-3 (n) was tested against KATO-III cells in the presence of IFN-g (20 ng/ml) or HSC3 cells in 18-h 51Cr-release
assay at the indicated E/T ratios. Data represent mean 6 SD of triplicate samples. Similar results were obtained in three independent experiments. 
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Thus, we used 18-h 
 
51
 
Cr-release assay to evaluate the
TRAIL- or TWEAK-mediated cytotoxicity in the follow-
ing experiments. As represented in Fig. 1 C, both KATO-
III cells and HSC3 cells were killed by TWEAK and
TRAIL transfectants in an E/T ratio–dependent manner,
whereas KATO-III cells were much less sensitive to
TWEAK transfectant than HSC3. Similarly, hTWEAK/
L5178Y cells, but not L5178Y cells, exhibited cytotoxic
activity against these target cells (data not shown).
We and others have reported that some members of the
TNF family, such as TNF-
 
a
 
 and FasL, undergo processing
by certain proteinases, resulting in the release of functional
soluble forms from the cell surface (15, 17). Likewise, we
observed that the culture supernatants of the hTWEAK/
2PK-3 and hTWEAK/L5178Y cells, but not those of pa-
rental cell lines, exhibited substantial cytotoxicity against
HSC3 and KATO-III cells (data not shown). This sug-
gested that TWEAK could be also released as a functional
soluble form.
Characterization of Anti-hTWEAK mAbs. To character-
ize the expression and function of hTWEAK, we generated
two mAbs that specifically bind to hTWEAK and block its
cytotoxic activity. Hybridomas were prepared from spleno-
cytes from mice immunized with the hTWEAK/2PK-3
cells. Two hybridomas producing CARL-1 and CARL-2
mAbs (mouse IgG3/k and IgM/k, respectively) were se-
lected by their ability to block CD8–TWEAK cytotoxicity.
As represented in Fig. 2 A, both CARL-1 and CARL-2
mAbs neutralized CD8–TWEAK cytotoxicity against HSC3
cells in a dose-dependent manner; CARL-1 was more ef-
fective than CARL-2. Both CARL-1 and CARL-2 reacted
with hTWEAK/2PK-3, but not with 2PK-3, as estimated
by cell surface staining (Fig. 2 B). These mAbs also stained
hTWEAK/L5178Y but not L5178Y, hFasL/2PK-3, or
hTRAIL/2PK-3 (data not shown), indicating the specific
binding of CARL-1 and CARL-2 to hTWEAK.
Expression of TWEAK on IFN-g-stimulated Monocytes.
Although the expression of TWEAK at the mRNA level
has been demonstrated in various tissues and cells (4), little
is known about its expression and regulation at the pro-
tein level. Thus, we first examined the expression of
TWEAK on human PBMCs by staining with the anti-
hTWEAK mAb CARL-1. No significant level of cell sur-
face TWEAK expression was observed on CD31CD562 T
cells, CD32CD561 NK cells, CD32CD191 B cells, or
CD141 monocytes in freshly isolated PBMCs (data not
shown). We previously demonstrated that the expression of
other death-inducing ligands of the TNF family such as
FasL and TRAIL could be induced on peripheral blood
(PB) T cells upon stimulation with certain mitogens or cy-
tokines (15, 18). However, even after the stimulation with
PHA, immobilized anti-CD3 mAb, IFN-a, IFN-g (Fig. 3
A), IL-2, IL-4, IL-12, IL-15, or IL-18 (data not shown) for
24–48 h, PB T cells did not express detectable level of
TWEAK on their surfaces. Furthermore, in contrast to the
FasL and TRAIL that were inducible on NK cells upon IL-2
stimulation (19, 20), no detectable TWEAK expression was
found on IL-2–activated NK cells (data not shown).
It is well known that LPS strongly induces TNF-a pro-
duction by monocytes. Furthermore, a recent study by
Griffith et al. (13) showed that TRAIL could be induced
on IFN-a– or IFN-g–stimulated monocytes. Thus, we
next examined whether surface TWEAK expression could
also be induced on PB monocytes by LPS, IFN-a, IFN-g,
or GM-CSF. Purified monocytes were cultured with IFN-a
(200 U/ml), IFN-g (100 ng/ml), LPS (20 mg/ml), or
GM-CSF (100 ng/ml) for 12 h, and the expression of
TWEAK and TRAIL was then examined by cell surface
staining with CARL-1. As represented in Fig. 3 B, a re-
markable TWEAK expression could be observed on IFN-
g–stimulated monocytes. Interestingly, in contrast to the
TRAIL expression that could be equivalently induced by
both IFN-a and IFN-g, TWEAK could be induced by
IFN-g but not IFN-a. Neither GM-CSF nor LPS was ef-
fective in inducing TWEAK and TRAIL expression.
These results indicated a unique expression of TWEAK on
IFN-g–stimulated monocytes. We also examined the ki-
netics of TWEAK expression after stimulation with IFN-g.
As represented in Fig. 3 C, TWEAK appeared at 3 h and
Figure 2. Characterization of anti-hTWEAK mAbs. (A) Inhibition of
TWEAK cytotoxicity. Cytotoxic activity of CD8–TWEAK (100 ng/ml)
was tested against HSC3 cells in the presence of serially diluted anti-
hTWEAK mAbs, CARL-1 (d) or CARL-2 (s), by the WST assay. Data
represent mean 6 SD of triplicate samples. Similar results were obtained
in three independent experiments. (B) Cell surface staining of hTWEAK
transfectant. 2PK-3 and hTWEAK/2PK-3 cells were stained with bio-
tinylated CARL-1 or CARL-2, followed by PE-labeled avidin (white
histograms). Dark histograms indicate background staining with biotiny-
lated control mAb plus PE-labeled avidin.1377 Nakayama et al. Brief Definitive Report
reached a peak at 12 h. A similar kinetics of TRAIL ex-
pression was observed (data not shown).
Involvement of TWEAK in IFN-g–stimulated Monocyte Cy-
totoxicity. It has been reported that monocytes exerted cy-
totoxicity against some kinds of tumor cells, especially after
the stimulation with IFN-g (10). We then examined
whether TWEAK is involved in the IFN-g–stimulated
monocyte cytotoxicity against tumor cells. We used highly
TWEAK- and TRAIL-sensitive HSC3 cells and highly
TRAIL- and weakly TWEAK-sensitive KATO-III cells as
target cells. Neutralizing anti-TWEAK mAb (CARL-1)
and neutralizing anti-TRAIL mAb (RIK-2) were used to
assess the contribution of TWEAK and TRAIL to the cy-
totoxicity, respectively.
As shown in Fig. 4, IFN-g–stimulated monocytes exhib-
ited substantial cytotoxicity against HSC3 cells that was
partially inhibited by either CARL-1 or RIK-2 alone and
almost completely abrogated by the combination of both
mAbs. This indicated that TWEAK and TRAIL expressed
on IFN-g–stimulated monocytes mostly account for the
cytotoxic activity of IFN-g–stimulated monocytes against
HSC3 cells. In contrast, while IFN-g–stimulated mono-
Figure 3. Expression of TWEAK
on human PB T cells and monocytes.
(A) Expression of TWEAK on human
PB T cells. PBMCs were cultured for
24 h on plates precoated with anti-
CD3 mAb (10 mg/ml) or in the pres-
ence of PHA (20 mg/ml), IFN-a (200
U/ml), or IFN-g (100 ng/ml). The
cells were then stained with bio-
tinylated CARL-1, followed by PE-
labeled avidin and FITC-labeled anti-
CD3 mAb. White histograms indicate
the staining with CARL-1 on elec-
tronically gated CD31 T cells. Dark
histograms indicate the background
staining with biotinylated control
mAb and PE-labeled avidin. Similar
results were obtained with PBMCs
from three individuals. (B) Expression
of TWEAK and TRAIL on human
PB monocytes. Purified monocytes
were stimulated with IFN-a (200
U/ml), IFN-g (100 ng/ml), LPS (20
mg/ml), or GM-CSF (100 ng/ml) for
12 h and then stained with biotiny-
lated CARL-1 and PE–avidin (white
histograms). Dark histograms indicate
the background staining with biotiny-
lated control mAb and PE–avidin.
Similar results were obtained with
monocytes from three individuals. (C)
Time course of TWEAK expression
on monocytes after stimulation with IFN-g (100 ng/ml). After the indicated time periods, the cells were stained with biotinylated CARL-1 and PE–avidin
(white histograms). Dark histograms indicate the background staining with biotinylated control mAb and PE–avidin. Similar results were obtained with
monocytes from three individuals.
Figure 4. Contribution of TWEAK,
TRAIL, and TNF-a to IFN-g–stimulated
monocyte cytotoxicity. Purified monocytes
were stimulated with IFN-g (100 ng/ml)
for 12 h. Cytotoxic activity was then tested
against HSC3 and IFN-g–treated KATO-
III cells by 18-h 51Cr-release assay at an E/T
ratio of 50. Data represent mean 6 SD of
triplicate samples. Similar results were ob-
tained in three independent experiments.1378 Involvement of TWEAK in Monocyte Cytotoxicity
cytes also efficiently lysed KATO-III cells, CARL-1 alone
hardly inhibited this cytotoxicity. Even in combination
with RIK-2 that alone partially inhibited this cytotoxicity,
the addition of CARL-1 did not affect the cytotoxicity
against KATO-III cells, indicating little contribution of
TWEAK. As KATO-III cells were highly sensitive to
TNF-a–induced cell death (data not shown), we tested
neutralizing anti–TNF-a mAb in combination with RIK-2
and found that the addition of both mAbs mostly abrogated
the IFN-g–stimulated monocyte cytotoxicity against KATO-
III cells (Fig. 4). This indicated that TRAIL and TNF-a
mostly account for the IFN-g–stimulated monocyte cyto-
toxicity against KATO-III cells. These results suggested
that relative contributions of TWEAK, TRAIL, and TNF-a
appear to be determined by the susceptibility of individual
target cells to each death-inducing ligand.
Discussion
In this study, we investigated the expression and func-
tion of TWEAK in human PBMCs by using newly estab-
lished neutralizing mAbs against hTWEAK. No detectable
level of TWEAK expression was found on each subpopula-
tion of T cells, B cells, NK cells, and monocytes in freshly
isolated PBMCs. However, a remarkable level of TWEAK
expression could be induced on monocytes upon IFN-g
stimulation. IFN-g–stimulated monocytes lysed HSC3 tar-
get cells by using both TWEAK and TRAIL. These results
are the first indication that TWEAK is involved in mono-
cyte cytotoxicity and that IFN-g is a potent inducer of
TWEAK expression on monocytes.
As represented in Fig. 3, monocytes expressed a substan-
tial level of TWEAK upon IFN-g stimulation. In contrast,
T cells expressed no detectable level of TWEAK even af-
ter various stimulation including IFN-g. We also observed
that stimulation of NK cells with IFN-g did not in-
duce TWEAK expression (data not shown). Thus, so far,
TWEAK appears to be preferentially expressed on mono-
cytes. Molecular mechanisms for the restricted induction of
TWEAK in monocytes remain obscure. This could not be
explained by differential expression of IFN-gR on these
cells, as IFN-g upregulated MHC class I expression on T
cells and NK cells as well as on monocytes (data not shown).
Further study is now underway to explore the mechanisms
for monocyte-restricted induction of TWEAK by IFN-g.
A recent study using DR3–Ig fusion protein de-
monstrated the constitutive expression of DR3 ligand
(TWEAK?) on murine CD41 T cell clones, which was re-
sponsible for their cytotoxicity against mouse macrophages
(21). These results seem to be inconsistent with our finding
indicating the preferential expression of TWEAK on
monocytes. Moreover, we observed that human monocytes
were resistant to TWEAK-induced cell death in the pres-
ence or absence of IFN-g (data not shown). These conflict-
ing results might reflect possible differences between human
and mouse systems. However, it should be noted that the
definition of TWEAK as the DR3 ligand still remains con-
troversial. In our preliminary study, we could not demon-
strate the binding of hDR3–Ig fusion protein to our
hTWEAK transfectants (our unpublished data). Further-
more, we could not detect DR3 expression in HSC3
cells or IFN-g–treated HT-29 and KATO-III cells at the
protein or mRNA levels, despite their susceptibility to
TWEAK-induced cell death (our unpublished data). In this
respect, it is possible that another DR3 ligand distinct from
TWEAK was expressed on the murine T cell clones, which
might mediate the cytotoxicity against murine macrophages.
Of course, we also cannot rule out the possible induction of
TWEAK expression in lymphocytes in certain culture con-
ditions. Further studies are now underway to determine the
TWEAK expression on various subpopulations of leuko-
cytes, including PMNs and dendritic cells, after stimulation
with cytokines and inflammatory mediators.
A previous study demonstrated the release of soluble
TWEAK into the supernatant of 293-EBNA cells tran-
siently transfected with full-length TWEAK cDNA (4).
Consistently, we also observed soluble TWEAK in the su-
pernatant of our hTWEAK transfectants, as assessed by cy-
totoxicity against HSC3 cells and sandwich ELISA using
CARL-1 and CARL-2 mAbs (data not shown). Processing
of membrane-bound TNF-a leads to the release of soluble
form with substantial loss of biological activity against
TNFR-II (22). Similarly, naturally processed soluble form
of FasL mostly lacked cytotoxic activity and is speculated to
act as an antagonist against membrane-bound FasL (23). In
our preliminary study, we observed that the naturally pro-
cessed soluble TWEAK had as potent cytotoxic activity
(ED50  5 32 ng/ml) as CD8–TWEAK fusion protein
(ED50 5 37 ng/ml) against HSC3 cells. This suggests possi-
ble function of TWEAK as a diffusible cytokine produced
by IFN-g–stimulated monocytes. Further biochemical anal-
ysis will be needed to clarify whether the naturally pro-
cessed soluble TWEAK has biological activities similar to
those of membrane-bound TWEAK.
It has been reported that monocytes killed tumor cells
via TNF-a and TRAIL (9, 13). Here, we demonstrated an
additional pathway of monocyte cytotoxicity via TWEAK.
Thus, TWEAK, TRAIL, and TNF-a might be largely re-
sponsible for mediating human monocyte cytotoxicity
against various tumor cells. The relative contribution of
each effector molecule appears to be determined by the ac-
tivational state of monocytes and the sensitivity of individ-
ual tumor targets to each death-inducing ligand. A previous
study in the murine system reported a critical role of
monocytes in tumor rejection in vivo that was evoked by
endogenous IFN-g (24). Indeed, infiltration of monocytes
has been frequently observed in various tumors (25). Fur-
thermore, in a human clinical trial, adoptive transfer of
IFN-g–stimulated monocytes exerted some antitumor ef-
fects in patients (26). Direct cytotoxicity by IFN-g–stimu-
lated monocytes via death-inducing ligands might be in-
volved in the beneficial effects.
In addition to the ability to induce cell death in tumor
cells, TWEAK stimulates endothelial cells to proliferate in
vitro and induces angiogenesis in vivo (7). We also ob-
served that CD8–TWEAK induced intercellular adhesion1379 Nakayama et al. Brief Definitive Report
molecule (ICAM)-1 upregulation and IL-8 secretion in
human endothelial cells (our unpublished data). Therefore,
TWEAK produced by IFN-g–stimulated monocytes may
play important roles not only as an antitumor effector
mechanism but also as a proinflammatory cytokine. The
anti-TWEAK mAbs generated in this study will be useful
for further investigating the pathophysiological functions of
TWEAK.
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